<DOC>
	<DOCNO>NCT01502735</DOCNO>
	<brief_summary>This phase 1 study evaluate safety vaccine ( DENV-1 PIV ) prevention dengue fever .</brief_summary>
	<brief_title>Safety Study Vaccine ( DENV-1 PIV ) Prevent Dengue Disease</brief_title>
	<detailed_description>DENV infection cause self-limited incapacitate acute illness last four seven day . The illness characterize fever , headache , severe pain muscle , joint , pain behind eye , rash . DENV infection complicate development hemorrhagic fever ( DHF ) shock syndrome ( DSS ) , manifest plasma leakage bleed diathesis frank hemorrhage . DHF fatal least 0.5 % pediatric case rarely adults . People , particularly child , live hyper-endemic area antibody earlier dengue infection one serotype increase risk DHF subsequently infect another dengue virus serotype . Currently , specific anti-viral therapy exists . Therapy largely supportive . Mosquito control fail prevent dengue transmission ; therefore , prevention dengue vaccination important objective World Health Organization ( WHO ) many national government , include United States .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females 18 year age legal age consent ( whichever great ) 50 ( inclusive ) year age Negative screening laboratory test dengue , Japanese Encephalitis , West Nile , Yellow Fever viruses Healthy All subject must agree use contraception abstain sex enrollment trial completion Able provide inform consent able follow throughout trial period History Flavivirus infection history Flavivirus vaccine ( experimental license product ) include Japanese encephalitis , West Nile virus , Yellow fever , dengue Have know suspect hypersensitivity adverse reaction vaccine Have receive liveattenuated vaccine within 42 day prior initial injection Day 0 subunit kill vaccine within 30 day initial injection Day 0 Are pregnant breastfeed Known HIV , Hepatitis B and/or Hepatitis C infection Have acute illness , include oral body temperature great 100.4Â°F day vaccination Have occupational , social , medical concern would impact subject safety , interfere protocol adherence , affect subject 's ability give inform consent Have use immunomodulatory therapy ( use systemic corticosteroid chemotherapeutics may influence antibody development ) within past 6 month ; medication nutritional supplement know potentially could affect organ function within 30 day prior initial injection Have receive investigational drug vaccine participate drug product vaccine study within period 30 day prior Day 0 Have receive donate blood plasma within 90 day Day 0 ( plan receive donate blood plasma study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>dengue</keyword>
	<keyword>dengue fever</keyword>
	<keyword>monovalent dengue vaccine</keyword>
</DOC>